Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women With Optimally-Debulked Stage III Epithelial Ovarian Cancer

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed stage III ovarian epithelial, fallopian tube, or primary
peritoneal carcinoma

- Tumor involves one or both ovaries with microscopically confirmed peritoneal
metastasis outside the pelvis and/or regional lymph node metastasis

- No tumors of borderline or low malignant potential only

- Mixed Mullerian tumors allowed

- Must have optimal disease defined as no residual lesions after resection or residual
disease such that no single lesion measures greater than 1 cm in diameter

- Must have undergone staging exploratory laparotomy with tumor debulking within the
past 70 days

PATIENT CHARACTERISTICS:

Age:

- Not specified

Performance status:

- SWOG 0-1

Life expectancy:

- Not specified

Hematopoietic:

- Granulocyte count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

Hepatic:

- Bilirubin ≤ 2 times upper limit of normal (ULN)

- SGOT or SGPT ≤ 2 times ULN

Renal:

- Creatinine clearance ≥ 50 mL/min

Cardiovascular:

- No congestive heart failure

- No cardiac arrhythmia

- No myocardial infarction or unstable angina within the past 6 months

- Patients with a history of myocardial disease must not have ischemia or pathologic
arrhythmias and must have an ejection fraction > 50% by MUGA

Other:

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No active or uncontrolled infection

- No concurrent fever

- No grade 2 or greater sensory neuropathy

- No severe gastrointestinal symptoms (i.e., partial obstruction) and/or bleeding,
diarrhea, or abdominal tenderness suggestive of peritoneal irritation or infection

- No erythema or tenderness of abdominal incision or port site suggestive of underlying
infection

- No other malignancy within the past five years except adequately treated basal cell
or squamous cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No prior immunotherapy for ovarian cancer

Chemotherapy:

- No prior chemotherapy for ovarian cancer

Endocrine therapy:

- Not specified

Radiotherapy:

- No prior pelvic radiotherapy for ovarian cancer

Surgery:

- See Disease Characteristics

- Recovered from all reversible surgery-related toxic effects

Other:

- No other concurrent antitumor treatment

- No concurrent antibiotics for infection of undetermined etiology